Certainly a difficult few months for holders with the exit of a major fund, but lots of upside IMO...
1) The most clinically validated suite of smart-inhaler products in the world, multiple patents and registered designs. NICE acknowledges Adherium’s Smartinhaler™ as being more effective than current practice in asthma medication intake (FYI these guidelines inform current medical practice, even in AUS)
2) 510k FDA approved devices, targeting formal approval next qtr
3) Owns one of the worlds largest data sets of respiratory medication usage, developed over 15 years, which according to the last presentation can be monetized
4) 1.2mil worth of receipts last qtr and growing, transitioning to a SaaS model and launching in the US this FY
5) Simple value proposition, which is increased medication compliance and monitoring for asthma/emphysema = reduced morbidity (value adding to patients, clinicians and saves $ for health system with significantly less hospital presentations and disease 'flares')
6) Mid-way through a large clinical trial with primary partner and SH, Astrazeneca (market cap of 78billion, 4.4billion in sales from just two of their inhaled asthma/COPD drugs)
7) 50c SP on listing and another raise done mid-way through last year (to Fidelity) at the same price.
